PMID- 21283989
OWN - NLM
STAT- MEDLINE
DCOM- 20110912
LR  - 20231115
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 100
IP  - 7
DP  - 2011 Jul
TI  - Preparation, characterisation and entrapment of a non-glycosidic threitol 
      ceramide into liposomes for presentation to invariant natural killer T cells.
PG  - 2724-33
LID - 10.1002/jps.22500 [doi]
AB  - Dendritic cells (DCs) are able to present glycolipids to invariant natural killer 
      T (iNKT) cells in vivo. Very few compounds have been found to stimulate iNKT 
      cells, and of these, the best characterised is the glycolipid 
      alpha-galactosylceramide, which stimulates the production of large quantities of 
      interferon-gamma (IFN-gamma) and interleukin-4 (IL-4). However, alphaGalCer leads to 
      overstimulation of iNKT cells. It has been demonstrated that the alphaGalCer 
      analogue, threitol ceramide (ThrCer 2), successfully activates iNKT cells and 
      overcomes the problematic iNKT cell activation-induced anergy. In this study, 
      ThrCer 2 has been inserted into the bilayers of liposomes composed of a neutral 
      lipid, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), or 
      dimethyldioctadecylammonium bromide (DDA), a cationic lipid. Incorporation 
      efficiencies of ThrCer within the liposomes was 96% for DSPC liposomes and 80% 
      for DDA liposomes, with the vesicle size (large multilamellar vs. small 
      unilamellar vesicles) making no significant difference. Langmuir-Blodgett studies 
      suggest that both DSPC and DDA stack within the monolayer co-operatively with the 
      ThrCer molecules with no condensing effect. In terms of cellular responses, IFN-gamma 
      secretion was higher for cells treated with small DDA liposomes compared with the 
      other liposome formulations, suggesting that ThrCer encapsulation in this 
      liposome formulation resulted in a higher uptake by DCs.
CI  - Copyright (c) 2011 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Kaur, Randip
AU  - Kaur R
AD  - School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
FAU - Chen, Jili
AU  - Chen J
FAU - Dawoodji, Amina
AU  - Dawoodji A
FAU - Cerundolo, Vincenzo
AU  - Cerundolo V
FAU - Garcia-Diaz, Yoel R
AU  - Garcia-Diaz YR
FAU - Wojno, Justyna
AU  - Wojno J
FAU - Cox, Liam R
AU  - Cox LR
FAU - Besra, Gurdyal S
AU  - Besra GS
FAU - Moghaddam, Behfar
AU  - Moghaddam B
FAU - Perrie, Yvonne
AU  - Perrie Y
LA  - eng
GR  - G0400421/MRC_/Medical Research Council/United Kingdom
GR  - G1000800/MRC_/Medical Research Council/United Kingdom
GR  - 084923/WT_/Wellcome Trust/United Kingdom
GR  - 11331/CRUK_/Cancer Research UK/United Kingdom
GR  - 084923/B/08/7/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110131
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Galactosylceramides)
RN  - 0 (Liposomes)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Quaternary Ammonium Compounds)
RN  - 0 (Sugar Alcohols)
RN  - 0 (alpha-galactosylceramide)
RN  - 251IW5I21C (dimethyldioctadecylammonium)
RN  - 6DN82XBT5M (threitol)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EAG959U971 (1,2-distearoyllecithin)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/chemistry/*pharmacology
MH  - Cells, Cultured
MH  - Chemistry, Pharmaceutical
MH  - Dendritic Cells/*drug effects/immunology
MH  - Drug Compounding
MH  - Drug Stability
MH  - Galactosylceramides/administration & dosage/chemistry/*pharmacology
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Killer Cells, Natural/*drug effects/immunology
MH  - Kinetics
MH  - Liposomes
MH  - Particle Size
MH  - Phosphatidylcholines/*chemistry
MH  - Quaternary Ammonium Compounds/*chemistry
MH  - Solubility
MH  - Sugar Alcohols/administration & dosage/chemistry/*pharmacology
MH  - Technology, Pharmaceutical/methods
PMC - PMC3818697
MID - EMS55480
OID - NLM: EMS55480
EDAT- 2011/02/02 06:00
MHDA- 2011/09/13 06:00
PMCR- 2013/11/06
CRDT- 2011/02/02 06:00
PHST- 2010/11/12 00:00 [received]
PHST- 2010/12/13 00:00 [revised]
PHST- 2010/12/14 00:00 [accepted]
PHST- 2011/02/02 06:00 [entrez]
PHST- 2011/02/02 06:00 [pubmed]
PHST- 2011/09/13 06:00 [medline]
PHST- 2013/11/06 00:00 [pmc-release]
AID - S0022-3549(15)32063-3 [pii]
AID - 10.1002/jps.22500 [doi]
PST - ppublish
SO  - J Pharm Sci. 2011 Jul;100(7):2724-33. doi: 10.1002/jps.22500. Epub 2011 Jan 31.